Dual Academicians and Renowned Investor Unveil the 9th Annual New Drug Founders Conference, Spearheading Innovation in Biopharma
In an era where transformation and opportunity intertwine, technological innovation and global collaboration are pioneering new frontiers in pharmaceuticals. Like intrepid navigators, founders of novel therapeutics courageously confront the challenges of the industry, jointly charting a landscape brimming with infinite possibilities. With hope and confidence, we set sail once again to conquer this blue ocean of pharmaceuticals and create a brighter future!
We value every professional who is passionate about and committed to the biopharmaceutical field, and we look forward to exchanging ideas and inspiring wisdom with you at this industry gathering.This year's annual conference is now open.SectionFree Spots(Priority given to founders of new drugs, investors, and personnel in R&D/clinical departments for new drugs), deadline: June 5 at 13:00。
Welcome to click the link to register
Setting Sail, Riding the Crest of the Wave
Time：June 12–14, 2024
Organizer: Xinyao Club Management Co., Ltd.
Gold Sponsors: Crystal Pharmatech, Taimei Medical Technology, Tianyu Pharmaceutical, and Foshanho Pharma
Supporting Organizations: WuXi AppTec, ICON, Clarivate, Jingtian & Gongcheng, Bayer, Yipinhong Pharmaceutical Co., Ltd., Hongbo Medicine, Commerce & Finance Law Offices, PatSnap, TC-Group, BoSaitao, Prisun, Hengrui Medicine, Kaisei, Haijingge
Annual Meeting Agenda
Swipe up or down to view the detailed schedule for each section.
Visit & Exchange + Guandan Tournament for New Drug Founders
June 12, 13:00–18:00
Visit & Exchange + Guandan Tournament for New Drug Founders
Visit to the Hangzhou Future Sci-Tech City Exhibition Hall
New Drug Founders’ Closed-Door Exchange
June 13, 09:00–17:00
Exploring Strategies for European Biopharmaceutical Companies to Expand Globally:
New Opportunities in R&D, Regulatory Affairs, and Business Development Collaboration
Planned by: Sun JinquanCEO of Wosheng Pharmaceutical
June 13, 09:00-12:00
In-Depth Analysis of the Business Environment for Europe’s Biopharmaceutical Industry
Zhang Shumin, Catalan Trade and Investment Promotion Agency
Strategies and Practices for Data Compliance in European Market Expansion
Innovative Drugs Going Global: Regulatory and Operational Considerations for Conducting Clinical Trials in Europe
Su Heng, Head of Business Development, ICON China
Corporate Transformation and Upgrading:
Strategic Holistic Vision and the Path of Capital
Planned by: Leng YanManaging Partner, Mint Angel Fund
June 13, 13:30–17:00
Strategic Holistic Perspective and New Thinking in Business Management
Exploring the Path of Corporate Capital
Share: The Growth of Innovative Drug Companies from a Capital Perspective
Li Wenming, Partner at Hejun Capital
Discussion: Invite investors with a deep understanding of global expansion, a track record of investing in high-quality business development (BD) projects, and an integrated investment perspective spanning both primary and secondary markets to discuss new investment opportunities.
Li Ming, Partner at Lichen Investment Management
Li Wenming, Partner at Hejun Capital
Hong Tan, Partner at Legend Capital
Discussion: Inviting founders or business development (BD) practitioners who have recently closed transactions with multinational pharmaceutical companies featuring upfront payments exceeding several thousand US dollars to engage in an in-depth discussion on execution strategies and key practical considerations for successful BD.
Ding Qiang, CEO of Anrui Biotech
Qu Jiarun, Senior Vice President of BioMap
Discussion: Inviting CEOs of Biotech companies listed under Chapter 18A that have achieved profitability, as well as CEOs of startups that have completed major strategic transformations and generated hundreds of millions in revenue over the past year, to discuss commercialization and strategic transformation in biopharmaceutical companies.
Zhu Jun, CEO of Henlius
Tong Kun, CEO of Shenji Bio
Thematic Forum
June 13, 09:00-12:00
Discussing Frontiers in Autoimmune Diseases: Exploring New Strategies for Treatment and Disease Management
Planner: Zheng WeiyiChairman/CEO of Nuojing Life
Functional Plasticity of FOXP3+ Regulatory T Cells and Immunotherapy
Li Bin, Deputy Director of the Shanghai Institute of Immunology / Founder and Chairman of the Scientific Committee of Promab Biosciences
Exploration of Differentiated Cytokine Blockers in the Field of Autoimmune Diseases
Xiong Huizhong, Senior Director of Immunology at Innovent Biologics
Development of IRAK4 PROTAC Molecules in the Autoimmune Field for the Treatment of Atopic Dermatitis
To the CEO of Shaoyun Duoyu Biology
Investigation into the Application of Universal CD19 CAR-T Therapy in the Treatment of Autoimmune Diseases
Binghe Tan, Vice President of Production and CMC at Bangyao Bio
Roundtable Discussion
Li Bin, Deputy Director of the Shanghai Institute of Immunology
Founder/Chairman of the Scientific Committee, Pumei Biosciences
Fan Houxing, CEO of Tongnuokang Pharmaceutical
Tan Binghe, Vice President of Production and CMC at Bioray Laboratories
Xiang Shaoyun, CEO of Duoyu Biology
Hui Zhong Xiong, Senior Director of Immunology at Innovent Biologics
Zheng Weiyi, Chairman/CEO of Nuojing Life (Moderator)
The 3rd Annual Conference of CNS Entrepreneurship Club
June 13, 13:30-17:30
“Focus and Unite, Co-Create the Blueprint” — CNS Entrepreneurship Club’s 3rd Annual Meeting
Planner:Wang PengCEO of Ruichu Pharma
Wang YuqiangCEO of Magpie Pharmaceuticals
Zhuang YongjieCEO of KasiAi Bio
The Development Path of China’s First New Analgesic Drug to Receive FDA/NDA Acceptance
Wang Qingsong, CEO of Qingpu Bio
Clinical Translation and Application Prospects of In Situ Neuroregeneration Therapy
Sheng Jian, CEO of Shenxi Fusheng
Advances, Challenges, and Opportunities in Neuropeptide Therapeutics for the Nervous System
Chen Jinhui, CEO of Granco Bio
Roundtable Discussion: Progress in Clinical Research on Stroke at Home and Abroad
Chen Gong, Founder of Shenxi Resurrection
Professor, Guangdong-Hong Kong-Macao Institute of CNS Regeneration, Jinan University
Chen Rong, COO of Ningdan New Drug
Lin SuizhenCEO of Cytopeutics
Zhang Shuning, Clinical VP at Huode Bio
Zhang Gaoxiao, Deputy General Manager of Xique Pharmaceutical
Wang Yuqiang, CEO of Magpie Pharma (Moderator)
Roundtable Discussion: Research Advances in AD & Anti-Aging
Chen BozhouCEO of Jialishengke
Gao Yan, CEO of Weiming Brain Technology
Liu Jie, CEO of Bituo Kangwei Biology
Xiao Shifu, Director of Shanghai Mental Health Center
Wang Peng, CEO of Ruichu Pharma
Zhang Gaoxiao, Deputy General Manager of Xique Pharmaceutical
Zhou Xinfu, CSO of Aozong Biologics
Zhou Xianbo, CEO of Asnola
Zhuang Yongjie, CEO of Kasi Ai Bio (Moderator)
Wen Gu
June 13, 19:30-21:30
Planner:Yuan FangChairman/General Manager of Fangshenghe Pharmaceutical
The Power of Water
“Passion” Is the Eternal Flame
Stay firm in your conviction, go all out, and strive for victory!
——The Story of Huawei's Expansion into Europe
Xu Wenwei, Professor at Peking University, Tsinghua SEM, etc.
Keynote Address
June 14, 09:30-12:00
Keynote Address
Opening Remarks
Ding Lieming, Chairman/CEO of Beta Pharma, Honorary Chairman of the Annual Conference Organizing Committee
Symphony of the Code of Life
——A Journey into the Frontier of Biopharmaceutical Exploration
Nucleic Acid Therapeutics
Insights into the Development of the Biopharmaceutical Industry and Prospects for International Cooperation Opportunities
Roundtable Discussion
Cai Daqing, Founding Managing Partner of Sherpa Investment
Wang Peng, CEO of Ruichu Pharma
Liu Yuwen, Founding Partner of the Mint Angel Fund (Moderator)
Guest speakers are being continuously invited...
Thematic Forum
June 14, 13:30–17:30
Generative AI × Antibody Drugs: Exploring the Revolutionary Breakthroughs of Generative AI in Antibody Design
Planned by: Wu ChenbingCEO of Biocytogen
June 14, 13:30-17:30
Applications of Generative AI Algorithms in the Discovery of Biomacromolecules
Liu Fan, CEO of Xingkangyuan Biology
Title TBD
Tang Jian, CEO of BioGeometry
AI-Powered Innovation in Peptide and XDC Drug Development
Zheng Zheng, CEO of Luqianxing
AI+I/O
Yu Fuli, CEO of Jingfeng Bio
Roundtable Discussion
Liu Fan, CEO of Xingkangyuan Biology
Tang Jian, CEO of BioGeometry
Yu Fuli, CEO of Jinfeng Biotech
Zheng Zheng, CEO of Luqianxing
Wu Chenbing, CEO of EMBiologics (Moderator)
Computing and Clinical Medicine: Exploring the Path of Clinical Development in the AI Era
Planner: Zhao YuCo-Founder of Zheyuan Technology
Forum Title Sponsor: Taimei Medical Technology
June 14, 13:30–17:30
Construction and Reflections on the Disease-Specific Cohort Database of Shanghai Municipal Hospitals
Qian Biyun, Director of the Center for Clinical Research Promotion and Development, Shanghai Shenkang Hospital Development Center
Reflections on AI and Clinical Trial Design
Qi Xuebing, Chairman/President of Haijinge Pharmaceutical
Digital Intelligence Empowerment: Facilitating High-Quality Clinical Research
Zhao Lu, CEO of Taimei Medical Technology
Exploration and Practice of Virtual Clinical Trials in New Drug Development
Zheng Li, Director of the Clinical Trial Center, West China Hospital, Sichuan University
Applications of AI/ML in Clinical Trials and Regulatory Challenges
Yao Lixin, Southern Institute of Pharmaceutical Economics, National Medical Products Administration
Virtual Clinical Trials Implemented via Computational Medicine
Zhao Yu, Co-founder of Zheyuan Technology / Professor at the Western Institute of Computing Technology, Chinese Academy of Sciences / Deputy Director of the Turing-Darwin Laboratory
Roundtable Discussion
Ao Yi, Director of the Division of Strategy and Policy, China National Center for Biotechnology Development
Li GaoyangHead of DCT/CEO, Lingyan Innovation Health Technology
Ma Rui, Partner at JunHe LLP
Xiang Benxu, Executive Director (Presiding), Maibo Capital
Metabolic Drug Development: Source Innovation, Comprehensive Benefits, and Global Expansion for a Promising Future
Planner: Liu LipingCEO of Junshengtai Pharmaceuticals
June 14, 13:30–17:30
Clinical Demand for Innovative Drugs in Endocrinology and Metabolism
Qu Shen, Professor at Tongji University and Nanjing Medical University
Director, Institute of Obesity; Director, Thyroid Disease Research Institute, School of Medicine, Tongji University
Research and Development Trends of Long-Acting GLP-1 Receptor Agonists from the Perspective of Comprehensive Metabolic Benefits
Xu Wenjie, Senior Vice President/CBO at Yinnuo Medicine
Application of GLP-1R Antibodies in Metabolic Diseases
Wu Xinle, CSO of Xianweida Bio
Outlook on the Research, Development, and Industrialization of Sengliptin
Wang Tong, CSO of Shengshi Taike
Diabetes Medications: A Dazzling Array of Options
Li Jing, Chairman of Yaodu
Applications of Label-Free Imaging + AI Technology in NASH Drug Development
Teng Xiao, CTO of HistoIndex Group (Singapore) / General Manager of ChouTu Technology
Roundtable Discussion: Innovation Breakthroughs and Blue Ocean Strategies in the Global Market Competition for Metabolic Drugs
Li Jing, Chairman of Pharmadl
Xu Wenjie, Senior Vice President/CBO at Yinuo Medicine
Qu Shen, Professor at Tongji University and Nanjing Medical University
Director, Institute of Thyroid Diseases, School of Medicine, Tongji University; Director, Institute of Obesity
Wang Tong, CSO of Shengshi Taike
Wu Xinle, CSO of Sinocellbio
Liu Liping, CEO of Junshengtai Pharma (Moderator)
Register for the Conference
Register by scanning the following mini-program QR code:
We cordially invite you to participate in this year’s annual conference,Some free slots are now available for this year’s annual conference ((Priority given to founders of new drugs, investors, and personnel from departments such as new drug R&D/clinical trials), with a deadline of 13:00 on June 5.Please scan the QR code to view attendee benefits.
▍Accommodation and Transportation
Conference Hotel:
① Crowne Plaza Hangzhou Aux Center
Deluxe King Room / Twin Room:
CNY 850/room, including breakfast for two
RMB 800/room, single breakfast included
Reservation Phone: 19706825356 (Attend the New Drug Founders Annual Conference)
Hotel Address: Building 5, AUX Times Future City, Intersection of Chuangjing Road and Yuhangtang Road, Yuhang District, Hangzhou
Other Recommendations:(Recommended to book on Ctrip)
① All Seasons Hotel · Hangzhou Future Sci-Tech City Luting Road Branch
(1 km from the conference hotel)
Price: 300-350 yuan/night
② Hangzhou EFC Aomei International Hotel Apartment · Australia Center Branch
(350 meters from the conference hotel)
Price: 320-400 yuan/night
③ Muxi Future Apartment · Hangzhou EFC Euro-America Financial City Branch
(500 meters from the conference hotel)
Price: 230-350 yuan/night
Transportation Reference:
Hangzhou West Railway Station to Hotel - Taxi: 9 minutes / 20 yuan
Hangzhou North Railway Station to Hotel – Taxi: 35 minutes / 83 yuan
Hangzhou East Railway Station to Hotel - Taxi: 48 minutes / 90 yuan
Hangzhou Xiaoshan Airport to Hotel - Taxi: 60 minutes / 160 yuan
Hangzhou South Railway Station to Hotel - Taxi: 70 minutes / 160 yuan
High Five
Sponsorship for this year’s annual conference is now open. Please contact the Conference Secretariat to discuss collaboration opportunities.
▍Contact Us
Business Cooperation: Qi Jianhu 18625051129/wechat
RegistrationConsultation：Hou Jing 18018130850/wechat
Consultation and Registration:Xiao Xin18013607518/wechat
June 12-14 · Hangzhou
Seeking Like-minded Individuals
Set Sail Together, Ride the Crest of the Wave!